Neonatal infections caused by Gram-negative bacteria are associated with a significant risk of mortality and of long-term neurodevelopmental sequelae, especially when complicated by meningitis. Third-generation cephalosporins have a central role in the management of Gram-negative infections because of their excellent activity against these organisms and their ability to achieve high levels in the cerebrospinal fluid. However, resistance to cephalosporins has increased as their use in the neonatal intensive care unit (NICU) has become more common. Ciprofloxacin, a fluoroquinolone derivative of nalidixic acid that acts by inhibiting bacterial DNA gyrase, 1 is effective against Gram-negative organisms and penetrates the cerebrospinal fluid well, 2 but its use in pediatric patients has been limited because of safety concerns. 3 We recently used ciprofloxacin to successfully treat an extremely low birth weight infant with multidrug-resistant Klebsiella pneumoniae infection.
PATIENT REPORT
A 585-gm girl was born by cesarean section at 26 weeks' gestation to a mother being treated with ampicillin and gentamicin for chorioamnionitis. The infant received ampicillin and cefotaxime for 2 weeks for presumptive infection. She then developed signs of possible necrotizing enterocolitis, and the antibiotics were changed to vancomycin, clindamycin, and amikacin, which were administered for 7 days. In both cases, blood cultures were negative but treatment was continued because the infant had signs of infection. In addition, it was felt that the culture results might be unreliable because intrapartum antibiotics had been administered and because cultures can be negative in patients with necrotizing enterocolitis. While on antibiotics, the infant's blood culture grew Candida lusitaniae, which was treated with a 4-week course of amphotericin and 5-flucytosine.
At 23 days of age the infant developed signs of infection and cultures of blood and cerebrospinal fluid grew K. pneumoniae, which was resistant to third-generation cephalosporins and to amikacin but sensitive to ciprofloxacin and gentamicin. The cerebrospinal fluid was not bloody but only enough specimen was obtained to send for culture. In consultation with the Pediatric Infectious Diseases Service, it was decided that the benefits of treatment with ciprofloxacin outweighed the potential risks. The infant received intravenous ciprofloxacin, 10 mg/kg per dose every 12 hours, in combination with gentamicin for 25 days.
Subsequent blood and cerebrospinal fluid cultures were negative. Our patient did not develop any joint swelling or inflammation while 
receiving ciprofloxacin. The infant did experience a transient elevation in liver enzymes and uric acid that resolved despite continuation of therapy. (Table 1 ). The infant's alkaline phosphatase level increased during therapy and continued to rise after ciprofloxacin was discontinued; this was thought to be caused by rickets of prematurity. Thrombocytopenia was present before beginning ciprofloxacin, did not worsen during therapy, and resolved with the successful treatment of the infections (Table 2) . Ten days after completion of ciprofloxacin therapy, the infant was found to have Staphylococcus epidermidis in her blood. This pathogen was treated with vancomycin. She developed no more infections and was discharged home at 4 months of age weighing 2175 gm. Serial cranial ultrasound examinations were normal. CT and magnetic resonance scans of the brain showed no parenchymal abnormalities, and mild cerebral atrophy could not be ruled out. Brainstem auditory evoked potentials showed an increased hearing threshold with normal conduction time. The results of a neurologic examination were normal.
DISCUSSION
Adverse drug effects are seen in 5% to 15% of adults treated with ciprofloxacin, and therapy must be discontinued because of toxicity in 1% to 2%. Gastrointestinal (nausea, vomiting, and diarrhea), central nervous system (headache, agitation, dizziness, and, rarely, seizures), and dermatologic (allergic or photosensitive rashes) side effects are most common. Abnormal liver function tests, leukopenia, and eosinophilia are seen less frequently. Ciprofloxacin inhibits the hepatic metabolism of theophylline, potentially increasing the theophylline level.
1 Although hypersensitivity reactions appear to be uncommon, occurring in 0.25% of 13,143 patients in a Japanese survey, they are potentially serious. 4 Anaphylactoid reactions have been described in both pediatric and adult patients treated with ciprofloxacin; some of these patients developed hypotension and respiratory distress and required hospitalization. 5, 6 Purpuric skin lesions with local venospasm in a pediatric patient receiving intravenous ciprofloxacin has been reported, 7 as has acute encephalopathy. 8 In both of these cases, the clinical abnormalities resolved when the drug was discontinued.
While the toxicity seen with ciprofloxacin in adults is reversible, the drug has been found to cause irreversible damage to cartilage in juvenile laboratory animals, leading to limitations in its use in pediatric patients. 9 Nevertheless, ciprofloxacin has been used on a compassionate basis in children in certain clinical situations in which it has specific advantages, such as the oral treatment of pseudomonas infections in cystic fibrosis, 3 the treatment of shigellosis, 10 and the treatment of multidrug-resistant typhoid fever. 11 The published experience with ciprofloxacin in pediatric patients suggests that the drug is effective and that significant toxicity is uncommon. 9 An acute ar- thropathy, which resolves without sequelae, has been reported in children treated with ciprofloxacin, 12 but the irreversible arthropathy described in experimental animals appears to occur rarely if at all. 13 Growth in children treated with ciprofloxacin has been found to be normal, 14 and ciprofloxacin-treated pediatric patients monitored by magnetic resonance imaging have not developed the characteristic cartilaginous abnormalities seen in experimental animals. 15 Ciprofloxacin has also been used to treat systemic sepsis, 16 meningitis, 2 and brain abscess 17 caused by multidrug-resistant organisms in infants, including small premature babies. The drug appears to be effective in the neonate, and significant toxicity seems to be uncommon, even in extremely low birth weight infants. One report did link the use of ciprofloxacin to greenish discoloration of the teeth, 18 and an infant has been reported who developed pseudomembranous colitis with perforation in association with exposure to ciprofloxacin in breast milk. 19 It is important to remember that the neonatal experience with ciprofloxacin has been relatively limited, and it would be incorrect to assume that the drug is safe in neonates based on the more extensive, generally favorable experience with older children.
The use of broad spectrum antibiotics in the NICU increases colonization with pathogenic bacteria and fungi and promotes the emergence of resistant organisms. 20 In retrospect, it appears likely that the antibiotics that our patient received contributed to the development of her fungal and multidrug-resistant bacterial infections. Although treatment appeared indicated at the time, our experience demonstrates that empiric antibiotic therapy is not without risk. As with other antibiotics, the increased use of ciprofloxacin has led to an increase in resistance, which is mediated by an alteration in the organism's DNA gyrase or a change in the permeability of the cell membrane to the drug. 3 An increase in the prevalence of ciprofloxacinresistant salmonella, Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa have all been reported [21] [22] [23] in association with increased ciprofloxacin usage. Treatment failure resulting from the development of ciprofloxacin resistance by salmonella during therapy has also been described. 24 The indiscriminate use of ciprofloxacin should be avoided in order to limit the development of resistance.
As resistant Gram-negative organisms become more of a problem in the NICU, neonatologists should be aware of the possible role of ciprofloxacin in their management. Our experience, along with that of others, suggests that ciprofloxacin can be effective in the treatment of serious neonatal infections, including those involving the central nervous system, and that adverse effects are not common. However, safety concerns remain and the use of ciprofloxacin in the NICU should be restricted to the treatment of serious infections for which an alternative antibiotic is not available. Patients should be carefully monitored for evidence of drug toxicity while on therapy.
